Sagility Reports Strong Q2 FY27 Results and Chirok Health Acquisition
Sagility Ltd · Financial Result · 23 Oct 2026, 12:05 am
Sagility Reports Strong Q2 FY27 Results and Chirok Health Acquisition Sagility Limited delivered solid Q2 FY27 consolidated revenue of ₹20,321 million, up 22.5% YoY (12.2% CC), driven by 24.4% growth in its Payer vertical. Adjusted EBITDA increased 23.0% YoY to ₹5,353 million with margins expanding to 26.3%, while reported PAT grew 13.3% YoY to ₹2,842.12 million. The company declared an interim dividend of ₹0.15 per share. In a key strategic move, Sagility signed a definitive agreement to acquire US-based Chirok Health LLC for up to US$32.35 million, bolstering its provider RCM and clinical documentation capabilities.
Original exchange filing (PDF)
More announcements from Sagility Ltd
- The Company has made grant of stock options under the Employee Stock Options and Performance Stock Units Scheme 2026 of the Company · 14 Nov 2026
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 02, 2026 for Sagility BV · 03 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sagility B.V. · 03 Nov 2026
- Transcript of Earnings Call held on October 22, 2026 · 29 Oct 2026
- Communication to Shareholders regarding TDS on Interim Dividend FY2026-27 · 23 Oct 2026
- Disclosure of Investor Call Recording Q2FY27 · 23 Oct 2026
- Board approves Interim dividend for FY 2026-27 · 23 Oct 2026
- Corporate Action - Record date intimation for Interim dividend FY 2026-27 · 23 Oct 2026
